Short answer
CareDx, Inc. (CDNA) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $100M (up 20.7% year over year) with net income of $2M.
Q3 2025 key financials · XBRL
- Revenue
- $100M
- +20.7% YoY · +15.4% QoQ
- Net income
- $2M
- +122.6% YoY · +119.5% QoQ
- Operating margin
- -0.2%
- EPS (diluted)
- $0.03
- +121.4% YoY · +118.8% QoQ
Source: XBRL data from the CareDx, Inc. (CDNA) Q3 2025 10-Q on SEC EDGAR. USD.
CareDx, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Proposed MolDX draft LCD (July 17, 2025) may impose coverage criteria, utilization limits, bundled payments, risking reduced reimbursement
- Regulatory risk: Medicare reimbursement under new CPT code 0540U subject to repricing; potential $88 rate cut for AlloSure Kidney starting Jan 2026
- Legal risk: Ongoing dispute with significant Medicare Advantage payer over denied or underpaid claims, with risk of 18-month retrospective recoupment
- Market risk: Slow clinician adoption due to entrenched biopsy practices and reimbursement incentives favoring biopsies over CareDx tests
- Financial risk: Accumulated deficit $719M as of Sept 30, 2025 despite net income $1.7M for quarter; expectation of net losses for several more years
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CareDx, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.